Cargando…

Immunoglobulin M Paraproteinaemias

Monoclonal paraproteinaemia is an increasingly common reason for referral to haematology services. Paraproteinaemias may be associated with life-threatening haematologic malignancies but can also be an incidental finding requiring only observation. Immunoglobulin M (IgM) paraproteinaemias comprise 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Girard, Louis-Pierre, Soekojo, Cinnie Yentia, Ooi, Melissa, Poon, Li Mei, Chng, Wee-Joo, de Mel, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352433/ https://www.ncbi.nlm.nih.gov/pubmed/32630470 http://dx.doi.org/10.3390/cancers12061688

Ejemplares similares

Immunoglobulin M Monoclonal Gammopathies of Clinical Significance
por: Girard, Louis-Pierre, et al.
Publicado: (2022)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Potential Clinical Application of Genomics in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2018)

Natural History and Prognostic Factors at First Relapse in Multiple Myeloma
por: Wang, Chen, et al.
Publicado: (2020)

Genomic characterization of functional high-risk multiple myeloma patients
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2022)

Fibrillary Glomerulonephritis and Monoclonal Gammopathy: Potential Diagnostic Challenges
por: Da, Yi, et al.
Publicado: (2022)

Nucleolar organiser regions in myeloma and benign paraproteinaemia.
por: Bryan, R. L., et al.
Publicado: (1990)

Stem-cell transplantation in multiple myeloma: how far have we come?
por: Soekojo, Cinnie Y., et al.
Publicado: (2019)

Epicardial and visceral adipose tissue in relation to subclinical atherosclerosis in a Chinese population
por: Ei Ei Khaing, Nang, et al.
Publicado: (2018)

Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma
por: Jia, Yunlu, et al.
Publicado: (2021)

STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019)

Tumor-Associated Macrophages and Related Myelomonocytic Cells in the Tumor Microenvironment of Multiple Myeloma
por: Wang, Samuel S. Y., et al.
Publicado: (2022)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2019)

Molecular pathogenic pathways in extranodal NK/T cell lymphoma
por: de Mel, Sanjay, et al.
Publicado: (2019)

Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis
por: Chan, Wee-Lee, et al.
Publicado: (2023)

The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation
por: de Mel, Sanjay, et al.
Publicado: (2018)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
por: Li, Boheng, et al.
Publicado: (2019)

Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders
por: de Mel, Sanjay, et al.
Publicado: (2019)

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2022)

Recent advances in acute promyelocytic leukaemia
por: Ng, Chin-Hin, et al.
Publicado: (2017)

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
por: Jia, Yunlu, et al.
Publicado: (2019)

Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma
por: Xiong, Sinan, et al.
Publicado: (2021)

Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers
por: Li, Boheng, et al.
Publicado: (2021)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival
por: de Mel, Sanjay, et al.
Publicado: (2022)

Necrotizing Fasciitis in Hematological Patients: Enterobacteriaceae Predominance and Limited Utility of Laboratory Risk Indicator for Necrotizing Fasciitis Score
por: Foo, Rui Min, et al.
Publicado: (2015)

Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: from molecular pathogenesis to therapeutic target
por: Zhou, Jianbiao, et al.
Publicado: (2015)

Update on the hyper immunoglobulin M syndromes
por: Davies, E Graham, et al.
Publicado: (2010)

The emerging roles of exosomes in leukemogeneis
por: Zhou, Jianbiao, et al.
Publicado: (2016)

Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)

Tumor-derived exosomes in colorectal cancer progression and their clinical applications
por: Zhou, Jianbiao, et al.
Publicado: (2017)

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies
por: Zhou, Jianbiao, et al.
Publicado: (2018)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Targeting NF-κB Signaling for Multiple Myeloma
por: Wong, Ada Hang-Heng, et al.
Publicado: (2020)

The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies
por: Arora, Loukik, et al.
Publicado: (2018)

Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies
por: Mustafa, Nurulhuda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4nfc8c12osr56ikc9ngi64ktu5